Copyright
©The Author(s) 2016.
World J Hepatol. Jul 28, 2016; 8(21): 863-873
Published online Jul 28, 2016. doi: 10.4254/wjh.v8.i21.863
Published online Jul 28, 2016. doi: 10.4254/wjh.v8.i21.863
Mode of actions | Target | Stage of development | Ref. |
Entry inhibitions | NTCP | Myrcludex in phage 2 | [14,123] |
cccDNA | |||
Formation inhibitions | DSS | Preclinical | [99] |
Transcription inhibitions | ASO | IONIS-HBVRx in phase 1 | [98] |
Destabilization/degradation | ZFN | Preclinical | [100,101] |
TALEN | Preclinical | [102,103] | |
CRISPR/Cas9 | Preclinical | [109-117] | |
SiRNA | PgRNA | ARC-520 in phase 2 | [95] |
Nucleocapsid assembly inhibitions | Capsid formation | BAY4109 in phase 1 | [93,95] |
NV1221 in phase 1 | [93,95] | ||
Reverse transcription inhibitions | Polymerase | TAF in phase 3 | [93,94] |
Cmx157 in phase 1/2 | [93,95] | ||
HBsAg release inhibitions | HBsAg secretion | Preclinical | [109] |
HBsAg secretion | Rep2139 in phase 1/2 | [110] | |
Immune modulating | TLR-7 agonist | GS-9620 in phase 2 | [67,68] |
HBV-specific | Preclinical | [84] | |
cIAPS | Preclinical | [86] |
- Citation: Tajiri K, Shimizu Y. New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol 2016; 8(21): 863-873
- URL: https://www.wjgnet.com/1948-5182/full/v8/i21/863.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i21.863